Literature DB >> 17253607

Granulocyte-colony stimulating factor administration after myocardial infarction in a porcine ischemia-reperfusion model: functional and pathological effects of dose timing.

Nirat Beohar1, James D Flaherty, Charles J Davidson, Mladen Vidovich, Seema Singhal, Jonathan A Rapp, Ata Erdogan, Daniel C Lee, Chidambaram Rammohan, Adam Brodsky, Edwin Wu, Karen Pieper, Renu Virmani, Robert O Bonow, Jayesh Mehta.   

Abstract

BACKGROUND: Acute MI results in cardiomyocyte death, left ventricular (LV) dysfunction and adverse remodeling. The use of growth factors may prevent this. The aim of this study was to assess early and delayed administration of granulocyte colony-stimulating factor (G-CSF) in a porcine model of myocardial infarction (MI) and reperfusion.
METHODS: MI was induced by balloon occlusion followed by reperfusion. There were 3 groups: Control (n = 11), Early (n = 17), and Delayed treatment (n = 8). The Early group received G-CSF 10 microg/kg/d every other day for 20 days beginning immediately. The Delayed group received G-CSF 10 microg/kg/d daily for 10 days beginning on day 5. Magnetic resonance imaging was performed on days 5 and 56. LV end-diastolic volumes (EDV), end-systolic volumes, ejection fraction, expansion index, sphericity index, thinning ratio, and infarct mass were calculated. Histology was analyzed at 56 days.
RESULTS: At 56 days the change in EDV was 53% less in the Early (p = 0.005) and 24% greater in the Delayed (p = NS) group versus Control. The Delayed group also showed a 60% increase in normalized infarct mass (p = 0.055) and an 88% increase in expansion index (p = 0.003). Both groups had significantly less capillary density in the infarct border zone. The Delayed also had decreased arteriolar density in the mid scar.
CONCLUSIONS: Early treatment with G-CSF after MI decreases ventricular dilatation, while delayed treatment has a deleterious effect on LV remodeling. This may be related to changes in myocardial vascularity. The effects of G-CSF therapy and its dose timing help to elucidate the results of recent human trials. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17253607     DOI: 10.1002/ccd.20925

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  5 in total

Review 1.  Granulocyte colony-stimulating factor for ischemic heart failure: should we use it?

Authors:  Marcelo Perim Baldo; Sérgio Lamêgo Rodrigues; José Geraldo Mill
Journal:  Heart Fail Rev       Date:  2010-11       Impact factor: 4.214

Review 2.  Rebuilding the damaged heart: the potential of cytokines and growth factors in the treatment of ischemic heart disease.

Authors:  Nirat Beohar; Jonathan Rapp; Sanjay Pandya; Douglas W Losordo
Journal:  J Am Coll Cardiol       Date:  2010-10-12       Impact factor: 24.094

3.  G-CSF and erythropoietin combination therapy for infarct repair: two plus two equals two? Editorial to: "Cytokine combination theray with erythropoietin and granulocyte colony stimulating factor in a porcine model of acute myocardial infarction" by F.S. Angeli et al.

Authors:  Carrie M Quinn; Buddhadeb Dawn
Journal:  Cardiovasc Drugs Ther       Date:  2010-12       Impact factor: 3.727

Review 4.  Hematopoietic cytokines for cardiac repair: mobilization of bone marrow cells and beyond.

Authors:  Santosh K Sanganalmath; Ahmed Abdel-Latif; Roberto Bolli; Yu-Ting Xuan; Buddhadeb Dawn
Journal:  Basic Res Cardiol       Date:  2011-05-04       Impact factor: 17.165

5.  Granulocyte colony-stimulating factor therapy for stem cell mobilization following anterior wall myocardial infarction: the CAPITAL STEM MI randomized trial.

Authors:  Benjamin Hibbert; Bradley Hayley; Robert S Beanlands; Michel Le May; Richard Davies; Derek So; Jean-François Marquis; Marino Labinaz; Michael Froeschl; Edward R O'Brien; Ian G Burwash; George A Wells; Ali Pourdjabbar; Trevor Simard; Harold Atkins; Christopher Glover
Journal:  CMAJ       Date:  2014-06-16       Impact factor: 8.262

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.